NASDAQ · PEPG
Healthcare · Biotechnology
$2.98
Down-$0.05 (-1.51%)
Updated Aug 14, 2026, 5:59 PM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
PEPG closed at $2.98 after 21 trading sessions, up 32.44% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 13, 2026 | $2.90 | $3.05 | $2.80 | $2.98 | 1.39M |
| Aug 12, 2026 | $2.86 | $2.98 | $2.86 | $2.90 | 768.01K |
| Aug 11, 2026 | $3.04 | $3.14 | $2.86 | $2.90 | 1.15M |
| Aug 10, 2026 | $2.90 | $3.04 | $2.75 | $2.99 | 1.53M |
| Aug 7, 2026 | $2.48 | $2.875 | $2.44 | $2.85 | 3.22M |
| Aug 6, 2026 | $2.10 | $2.46 | $2.06 | $2.41 | 4.48M |
| Aug 5, 2026 | $1.96 | $1.99 | $1.87 | $1.98 | 668.2K |
| Aug 4, 2026 | $1.88 | $1.95 | $1.84 | $1.93 | 357.21K |
| Aug 3, 2026 | $1.77 | $1.93 | $1.77 | $1.88 | 347.65K |
| Jul 31, 2026 | $1.83 | $1.8799 | $1.71 | $1.76 | 296.81K |
| Jul 30, 2026 | $1.72 | $1.78 | $1.68 | $1.78 | 467.03K |
| Jul 29, 2026 | $1.83 | $1.85 | $1.70 | $1.71 | 951.72K |
| Jul 28, 2026 | $1.88 | $1.8999 | $1.735 | $1.83 | 622.86K |
| Jul 27, 2026 | $1.95 | $2.00 | $1.8803 | $1.90 | 528.53K |
| Jul 24, 2026 | $2.11 | $2.181 | $1.92 | $1.93 | 735K |
| Jul 23, 2026 | $1.90 | $2.12 | $1.885 | $2.10 | 828.63K |
| Jul 22, 2026 | $2.10 | $2.14 | $1.88 | $1.92 | 1.06M |
| Jul 21, 2026 | $2.20 | $2.275 | $2.105 | $2.12 | 579.07K |
| Jul 20, 2026 | $2.25 | $2.35 | $2.17 | $2.20 | 490.45K |
| Jul 17, 2026 | $2.19 | $2.275 | $2.16 | $2.25 | 609.06K |
| Jul 16, 2026 | $2.37 | $2.39 | $2.2088 | $2.25 | 993.92K |
The latest Smart Investors Daily articles mentioning PEPG.
PEPG research
Company profile and research snapshot.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 16, 2026 | Craig-Hallum | Buy | — |
| May 13, 2026 | Wedbush | Outperform | — |
| Apr 1, 2026 | Wedbush | Outperform | — |
| Mar 31, 2026 | Wedbush | Outperform | — |
| Feb 25, 2026 | Oppenheimer | Outperform | — |
No generated briefing is available yet.
Benzinga · Aug 6, 2026
PepGen (NASDAQ:PEPG) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.29) by 10.34 percent. This is a 62.86 percent increase over losses of $(0.70) per share from the same
Benzinga · Aug 6, 2026
Independent Data and Safety Monitoring Board (DSMB) has recommended advancing the ongoing Phase 2 FREEDOM2-DM1 study evaluating PGN-EDODM1 in participants with myotonic dystrophy type 1 (DM1) into the third and highest
Benzinga · Jun 16, 2026
Craig-Hallum analyst Adam Vogel initiates coverage on PepGen (NASDAQ:PEPG) with a Buy rating and announces Price Target of $11.
Benzinga · Feb 18, 2026
Guggenheim analyst Debjit Chattopadhyay maintains PepGen (NASDAQ:PEPG) with a Buy and raises the price target from $6 to $7.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PEPG.
